KalVista Pharmaceuticals, Inc. , a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced the.
High parathyroid hormone in patients on dialysis is associated with greater intracoronary calcification and could increase their risk for major adverse cardiovascular events.
High parathyroid hormone in patients on dialysis is associated with greater intracoronary calcification and could increase their risk for major adverse cardiovascular events.